A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder

Development of a methodology to enhance safety

William Vaughn McCall, Ruth M. Benca, Peter B. Rosenquist, Mary Anne Riley, Chelsea Hodges, Brittany Gubosh, Laryssa McCloud, Jill C. Newman, Doug Case, Meredith Rumble, Mark Mayo, Kaitlin Hanley White, Marjorie Phillips, Andrew D. Krystal

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/aims: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. Methods: "Reducing Suicidal Ideation Through Insomnia Treatment" is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. Results: In total, 584 potential participants have undergone telephone screening; 67% of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26% of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64% of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51% of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7% of scheduled visits have been attended, with 93.8% adherence to the selective serotonin reuptake inhibitor and 91.6% adherence to the randomized hypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. Conclusion: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.

Original languageEnglish (US)
Pages (from-to)189-198
Number of pages10
JournalClinical Trials
Volume12
Issue number3
DOIs
StatePublished - Jun 11 2015

Fingerprint

Suicidal Ideation
Major Depressive Disorder
Outpatients
Randomized Controlled Trials
Safety
Suicide
Hypnotics and Sedatives
Serotonin Uptake Inhibitors
Sleep Initiation and Maintenance Disorders
Telephone
Hospitalization
Placebos
National Institutes of Health (U.S.)
Random Allocation
Psychiatry
Public Health
Guidelines
Therapeutics

Keywords

  • Randomized clinical trial
  • depression
  • fluoxetine
  • insomnia
  • outpatient
  • suicide
  • zolpidem

ASJC Scopus subject areas

  • Pharmacology

Cite this

A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder : Development of a methodology to enhance safety. / McCall, William Vaughn; Benca, Ruth M.; Rosenquist, Peter B.; Riley, Mary Anne; Hodges, Chelsea; Gubosh, Brittany; McCloud, Laryssa; Newman, Jill C.; Case, Doug; Rumble, Meredith; Mayo, Mark; White, Kaitlin Hanley; Phillips, Marjorie; Krystal, Andrew D.

In: Clinical Trials, Vol. 12, No. 3, 11.06.2015, p. 189-198.

Research output: Contribution to journalArticle

McCall, WV, Benca, RM, Rosenquist, PB, Riley, MA, Hodges, C, Gubosh, B, McCloud, L, Newman, JC, Case, D, Rumble, M, Mayo, M, White, KH, Phillips, M & Krystal, AD 2015, 'A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety', Clinical Trials, vol. 12, no. 3, pp. 189-198. https://doi.org/10.1177/1740774515573958
McCall, William Vaughn ; Benca, Ruth M. ; Rosenquist, Peter B. ; Riley, Mary Anne ; Hodges, Chelsea ; Gubosh, Brittany ; McCloud, Laryssa ; Newman, Jill C. ; Case, Doug ; Rumble, Meredith ; Mayo, Mark ; White, Kaitlin Hanley ; Phillips, Marjorie ; Krystal, Andrew D. / A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder : Development of a methodology to enhance safety. In: Clinical Trials. 2015 ; Vol. 12, No. 3. pp. 189-198.
@article{790b762b171c4288bb940906c58ec170,
title = "A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety",
abstract = "Background/aims: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. Methods: {"}Reducing Suicidal Ideation Through Insomnia Treatment{"} is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. Results: In total, 584 potential participants have undergone telephone screening; 67{\%} of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26{\%} of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64{\%} of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51{\%} of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7{\%} of scheduled visits have been attended, with 93.8{\%} adherence to the selective serotonin reuptake inhibitor and 91.6{\%} adherence to the randomized hypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. Conclusion: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.",
keywords = "Randomized clinical trial, depression, fluoxetine, insomnia, outpatient, suicide, zolpidem",
author = "McCall, {William Vaughn} and Benca, {Ruth M.} and Rosenquist, {Peter B.} and Riley, {Mary Anne} and Chelsea Hodges and Brittany Gubosh and Laryssa McCloud and Newman, {Jill C.} and Doug Case and Meredith Rumble and Mark Mayo and White, {Kaitlin Hanley} and Marjorie Phillips and Krystal, {Andrew D.}",
year = "2015",
month = "6",
day = "11",
doi = "10.1177/1740774515573958",
language = "English (US)",
volume = "12",
pages = "189--198",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder

T2 - Development of a methodology to enhance safety

AU - McCall, William Vaughn

AU - Benca, Ruth M.

AU - Rosenquist, Peter B.

AU - Riley, Mary Anne

AU - Hodges, Chelsea

AU - Gubosh, Brittany

AU - McCloud, Laryssa

AU - Newman, Jill C.

AU - Case, Doug

AU - Rumble, Meredith

AU - Mayo, Mark

AU - White, Kaitlin Hanley

AU - Phillips, Marjorie

AU - Krystal, Andrew D.

PY - 2015/6/11

Y1 - 2015/6/11

N2 - Background/aims: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. Methods: "Reducing Suicidal Ideation Through Insomnia Treatment" is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. Results: In total, 584 potential participants have undergone telephone screening; 67% of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26% of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64% of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51% of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7% of scheduled visits have been attended, with 93.8% adherence to the selective serotonin reuptake inhibitor and 91.6% adherence to the randomized hypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. Conclusion: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.

AB - Background/aims: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. Methods: "Reducing Suicidal Ideation Through Insomnia Treatment" is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. Results: In total, 584 potential participants have undergone telephone screening; 67% of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26% of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64% of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51% of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7% of scheduled visits have been attended, with 93.8% adherence to the selective serotonin reuptake inhibitor and 91.6% adherence to the randomized hypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. Conclusion: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.

KW - Randomized clinical trial

KW - depression

KW - fluoxetine

KW - insomnia

KW - outpatient

KW - suicide

KW - zolpidem

UR - http://www.scopus.com/inward/record.url?scp=84929148630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929148630&partnerID=8YFLogxK

U2 - 10.1177/1740774515573958

DO - 10.1177/1740774515573958

M3 - Article

VL - 12

SP - 189

EP - 198

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 3

ER -